Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...
Yaqrit secures NIHR grant for pivotal trials of its liver support device, DIALIVE, for patients with liver failure
Trial to assess intensive care liver support system across 13 UK centers, led by UCL, Royal Free, Kings College and Queen Elizabeth ...
Truthout16hOpinion
DHS Abducts Georgetown Postdoctoral Researcher Over Pro-Palestine Views
Human rights advocates say the researcher, Badar Khan Suri, is being punished for criticizing US foreign policy.
TMCnet1d
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review
The integration of Clinical Data Studio into ICON's service offerings helps unlock the full potential of the Medidata Data Experience, merging information from both Medidata and non-Medidata sources, ...
Anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients, study suggests
For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...
ICON Public Limited Company (ICLR) Slid on Disappointing Earnings
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
Central Lab Services Market worth US$8.18 billion by 2030with 6.5% CAGR | MarketsandMarkets
The global Central Lab Services/Clinical Trial Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR ...
Does ICON Public Limited Company (ICLR) have a Favorable Long-Term Outlook?
Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Some Philly patients worry about affording their medications as insurers cut coverage for weight-loss drugs
The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...